HUTCHMED China Ltd - Asset Resilience Ratio
HUTCHMED China Ltd (HCM) has an Asset Resilience Ratio of 73.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how HUTCHMED China Ltd's Asset Resilience Ratio has changed over time. Check HCM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down HUTCHMED China Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HCM market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.30 Billion | 73.92% |
| Total Liquid Assets | GBX1.30 Billion | 73.92% |
Asset Resilience Insights
- Very High Liquidity: HUTCHMED China Ltd maintains exceptional liquid asset reserves at 73.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
HUTCHMED China Ltd Industry Peers by Asset Resilience Ratio
Compare HUTCHMED China Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 1.95% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for HUTCHMED China Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for HUTCHMED China Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.92% | GBX1.29 Billion ≈ $157.46K |
GBX1.75 Billion ≈ $213.01K |
+20.39pp |
| 2024-12-31 | 53.54% | GBX682.15 Million ≈ $83.00K |
GBX1.27 Billion ≈ $155.03K |
+6.44pp |
| 2023-12-31 | 47.10% | GBX602.75 Million ≈ $73.34K |
GBX1.28 Billion ≈ $155.71K |
+16.23pp |
| 2022-12-31 | 30.86% | GBX317.72 Million ≈ $38.66K |
GBX1.03 Billion ≈ $125.25K |
-15.34pp |
| 2021-12-31 | 46.20% | GBX634.16 Million ≈ $77.16K |
GBX1.37 Billion ≈ $167.01K |
+18.64pp |
| 2020-12-31 | 27.56% | GBX199.55 Million ≈ $24.28K |
GBX724.12 Million ≈ $88.10K |
+6.37pp |
| 2019-12-31 | 21.19% | GBX98.54 Million ≈ $11.99K |
GBX465.12 Million ≈ $56.59K |
-19.20pp |
| 2018-12-31 | 40.39% | GBX214.91 Million ≈ $26.15K |
GBX532.12 Million ≈ $64.74K |
-5.27pp |
| 2017-12-31 | 45.66% | GBX273.03 Million ≈ $33.22K |
GBX597.93 Million ≈ $72.75K |
+38.58pp |
| 2016-12-31 | 7.09% | GBX24.27 Million ≈ $2.95K |
GBX342.44 Million ≈ $41.66K |
+6.74pp |
| 2015-12-31 | 0.35% | GBX800.00K ≈ $97.34 |
GBX229.75 Million ≈ $27.95K |
-5.37pp |
| 2014-12-31 | 5.72% | GBX12.53 Million ≈ $1.52K |
GBX218.94 Million ≈ $26.64K |
+3.09pp |
| 2010-12-31 | 2.64% | GBX4.21 Million ≈ $512.83 |
GBX159.93 Million ≈ $19.46K |
-42.87pp |
| 2006-12-31 | 45.51% | GBX60.54 Million ≈ $7.37K |
GBX133.04 Million ≈ $16.19K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more